PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 9934131

Epilepsy: a journey.

S Frost·L Laville
View original source ↗Export metadata ↓

Abstract

Epilepsy is a tendency to have recurrent fits or seizures, and for most people is an uncomfortable and socially unacceptable thing to witness. It is estimated that 420,000 people in the UK will develop the condition in one form or another, with the risk of death three times higher than in the general population. There are over forty different types of seizure; each type presents itself differently from one person to another. However, the cause of the epilepsy is always the same; it is due to abnormal electrical activity within the brain (Fenwick and Fenwick 1996). The aim of this Learning Unit is to improve the understanding of epilepsy among nurses.

Explore related subjects

AnticonvulsantsEpilepsyHumansSelf CareJournal ArticleResearch Support, Non-U.S. Gov'tReview

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

S Frost, L Laville. Epilepsy: a journey.. https://doi.org/10.7748/ns.13.6.4.s55

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2007

A double-blind placebo-controlled trial of zonisamide (zonegran) in the treatment of essential tremor.

Medical therapy for essential tremor (ET), a common movement disorder, is often inadequate. We performed a double-blind placebo-controlled randomized trial to evaluate the efficacy and tolerability of zonisamide (ZNS), an antiepileptic agent, in treating ET. Twenty patients (mean age, 60 +/- 15 years) with ET were randomized to receive ZNS or placebo. ZNS was initiated at a dosage of 100 mg/day and escalated to 200 mg/day at day 14. Patients were evaluated by accelerometry and the Fahn-Tolosa-Marin (FTM) rating scale at baseline and days 14 and 28, as well as the Clinical Global Impression (CGI-C) scale at day 28. At endpoint, subjects assigned to ZNS were taking a mean dosage of 160 +/- 50 mg/day. There were no significant improvements in the FTM total score or its subsections. Tremor amplitude as assessed by accelerometry significantly improved in the ZNS group compared to the placebo group at endpoint relative to baseline (-0.50 +/- 0.72 vs. 0.30 +/- 0.79 m/s(2); P = 0.03). On the CGI-C, 60% (n = 6) of patients in the ZNS group felt that their tremor was unchanged, while the remaining patients felt that their tremor was "minimally improved." Thirty percent (n = 3) of patients taking ZNS discontinued the study due to side effects (fatigue, headache, paresthesias) while taking 100 mg per day. ZNS did not provide significant improvements in clinical rating scales at study endpoint compared to placebo and was only modestly well tolerated. ZNS was effective in reducing tremor amplitude as measured by accelerometry.

Anticonvulsants↗